Pfizer, BMS Loan $50 Million for Anticoagulant
By

By
Pfizer and Bristol-Myers Squibb (BMS) have signed agreements in which each company will loan $25 million to Portola Pharmaceuticals, a South San Francisco, California-based biopharmaceutical company focused on thrombosis and…

BMS to Develop Virus Therapy for Cancer
By

By
Bristol-Myers Squibb (BMS) has entered into an agreement with PsiOxus Therapeutics, an immuno-oncolytic virus company located in Oxfordshire, UK, for the exclusive worldwide rights to NG-348, a preclinical-stage, “armed” oncolytic…

Novartis in Liver-Disease Drug Pact
By

By
Novartis has entered into an exclusive option, collaboration and license agreement with Conatus Pharmaceuticals, a San Diego-based biotechnology company focused on liver-disease therapies, to jointly develop emricasan, an investigational drug…

Allergan to Acquire Regenerative Medicine Company for $2.9 Billion
By

By
Allergan has agreed to acquire the LifeCell regenerative medicines business of Acelity, a San Antonio, Texas-headquartered wound care and regenerative medicine company, for $2.9 billion in cash, subject to customary…

Novartis to Acquire Eye Drug Company
By

By
Novartis has agreed to acquire the eye-drug company, Encore Vision, a privately held firm in Fort Worth, Texas focused on therapies for presbyopia, commonly known as farsightedness. With this acquisition,…

BMS in Pact to Develop Cancer Combo Therapy
By

By
Bristol-Myers Squibb has formed a clinical-trial collaboration with Calithera Biosciences, a clinical-stage biotechnology company headquartered in South San Francisco, California focused on small-molecule drugs for cancer treatment. The collaboration will…

Otsuka in $1-Billion Pact for Anemia Drug
By

By
Otsuka Pharmaceutical has entered into a collaboration and license agreement in the US with Akebia Therapeutics, a biopharmaceutical company headquartered in Cambridge, Massachusetts, for an anemia treatment, vadadustat. Vadadustat is…

Novartis in Licensing Deal for COPD Products
By

By
Novartis has entered into an exclusive license agreement with Sunovion Pharmaceuticals, a biopharmaceutical company headquartered in Marlborough, Massachusetts and a wholly owned subsidiary of Osaka, Japan-based Sumitomo Dainippon Pharma, for…

Novartis in Pact to Develop Cancer Drug
By

By
Novartis has entered into global license and supply agreements with Ligand Pharmaceuticals, a biopharmaceutical company headquartered in San Diego, to develop and commercialize an oral liquid cancer drug. The companies…

J&J Back in Talks with Actelion
By

By
Johnson & Johnson has confirmed that it has entered into exclusive negotiations with Actelion, an Allschwil, Switzerland-based biopharmaceutical company, regarding a potential transaction. For its part, Actelion also confirmed the…